TY - JOUR AU - Yu, Jifeng AU - Sun, Hao AU - Cao, Weijie AU - Han, Lijie AU - Song, Yongping AU - Wan, Dingming AU - Jiang, Zhongxing PY - 2020 DA - 2020/12/04 TI - Applications of gut microbiota in patients with hematopoietic stem-cell transplantation JO - Experimental Hematology & Oncology SP - 35 VL - 9 IS - 1 AB - Studies of the gut microbiota (GM) have demonstrated the close link between human wellness and intestinal commensal bacteria, which mediate development of the host immune system. The dysbiosis, a disruption of the microbiome natural balance, can cause serious health problems. Patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) may cause significant changes in GM due to their underlying malignancies and exposure to extensive chemotherapy and systemic antibiotics, which may lead to different disorders. There are complex and multi-directional interactions among intestinal inflammation, GM and immune reactivity after HSCT. There is considerable effect of the human intestinal microbiome on clinical course following HSCT. Some bacteria in the intestinal ecosystem may be potential biomarkers or therapeutic targets for preventing relapse and improving survival rate after HSCT. Microbiota can be used as predictor of mortality in allo-HSCT. Two different strategies with targeted modulation of GM, preemptive and therapeutic, have been used for preventing or treating GM dysbiosis in patients with HSCT. Preemptive strategies include enteral nutrition (EN), prebiotic, probiotic, fecal microbiota transplantation (FMT) and antibiotic strategies, while therapeutic strategies include FMT, probiotic and lactoferrine usages. In this review, we summarize the advance of therapies targeting GM in patients with HSCT. SN - 2162-3619 UR - https://doi.org/10.1186/s40164-020-00194-y DO - 10.1186/s40164-020-00194-y ID - Yu2020 ER -